Read our latest updates & insights

California’s Governor Gavin Newsom signed legislation to lower the cost of prescription drugs. The legislation, SB852, allows the California Health and Human Services Agency (CHHS) to develop manufacturing partnerships to produce or distribute generic prescription dru...

The University of Oxford announces it has commenced Ph II trials of adalimumab as a treatment for patients with COVID-19. The trial will enrol up to 750 patients from community care settings throughout the UK and is funded by the COVID-19 Therapeutics Accelerator, an initia...

Centus Biotherapeutics announces it has received EC marketing authorisation for Equidacent® (biosimilar bevacizumab). Equidacent® has been exclusively licensed to Fujifilm Kyowa Kirin Biologics on a worldwide basis.

The Alliance of Community Health Plans (ACHP) released a new report ‘Health Care 2030: ACHP’s Roadmap to Reform’ which calls for nonpartisan and practical changes to the American healthcare system. Among these proposed changes, ACHP has called for reforms ...

Significant biosimilar activities this week include
21 Sep 20 | EU | Alexion announced it has received a positive opinion from the EU’s CHMP for a new 100mg/mL formulation of Ultomiris® (ravulizumab).  The new formulation requires an infusion time of 0.4 hours t...

Innovent announces its ph III trial of Byvasda® (proposed bevacizumab biosimilar) in combination with Tyvyt® (sintilimab) met its primary endpoints of progression-free survival and overall survival. Innovent reported that the safety profile of both products was consistent w...

Accord Healthcare launches Zercepac® (biosimilar trastuzumab) in the UK. Zercepac® is indicated for HER2-positive early breast cancer, HER2-positive metastatic breast cancer and previously untreated HER2-positive metastatic gastric cancer and is available in a 150mg single-...

The International Generic and Biosimilar Medicines Association (IGBA) released a new policy paper which calls for the streamlining of biosimilar regulatory requirements, and renewed efforts in informing and educating healthcare community stakeholders.

The Australian Government announced it has joined the COVAX facility, committing an initial $123.2 million for the ability to purchase vaccines when they become available. The COVAX facility is a collaboration between Gavi, the Coalition for Epidemic Preparedness Innovation...

Dong-A ST announces sales approval for biosimilar darbepoetin from Japan’s Ministry of Health, Labour and Welfare.